S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

SLRN ACELYRIN Inc

3.17

-0.01 (-0.31%)

After Hours

Last Updated: 16:00:00

Delayed by 15 minutes

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

ACELYRIN (NASDAQ:SLRN)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more ACELYRIN Charts.

ACELYRIN (NASDAQ:SLRN)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more ACELYRIN Charts.

ACELYRIN Inc News

Form 8-K - Current report
Tuesday 10 December 2024 (2 weeks ago) • Edgar (US Regulatory)

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Tuesday 10 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Form S-3 - Registration statement under Securities Act of 1933
Wednesday 13 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 13 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 13 November 2024 (1 month ago) • Edgar (US Regulatory)

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
Wednesday 13 November 2024 (1 month ago) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Friday 8 November 2024 (2 months ago) • Edgar (US Regulatory)

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
Wednesday 6 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K/A - Current report: [Amend]
Monday 4 November 2024 (2 months ago) • Edgar (US Regulatory)

ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
Wednesday 16 October 2024 (2 months ago) • GlobeNewswire Inc.

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
Thursday 19 September 2024 (3 months ago) • GlobeNewswire Inc.

ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Sur
Tuesday 10 September 2024 (3 months ago) • GlobeNewswire Inc.

More ACELYRIN Inc News Articles

ELine Entertainment (CE)

Hallmark Venture (PK)

Asia Broadband (PK)

Virexit Technologies (PK)

Anavex Life Sciences

KULR Technology

Intergrated Cannabis Sol... (PK)

Digital Brand Media and ... (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions